# Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

> **NCT04932564** · PHASE2 · TERMINATED · sponsor: **Tata Memorial Centre** · enrollment: 1 (actual)

## Conditions studied

- Musculoskeletal Disease Other
- GVHD, Chronic

## Interventions

- **DRUG:** Leflunomide tablet

## Key facts

- **NCT ID:** NCT04932564
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-18
- **Primary completion:** 2024-06-25
- **Final completion:** 2024-06-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Issues with recruitment. Practice changes, including leflunomide use for CMV, have led to a lack of musculoskeletal GVHD cases. Only one patient enrolled in the trial will continue treatment as per standard care.
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932564, "Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04932564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*